There Is a Lack of Data on the Effect of Dose Optimization
In practice, dose adjustments are frequently implemented to enhance treatment efficacy. However, robust evidence supporting the effectiveness of these modifications is often lacking, says Dr. Peter Bossuyt in this MEDtalk. At ECCO 2025, Dr. Bossuyt presented the REScUE study, which examined ustekinumab dose optimization in Crohn’s disease patients experiencing secondary loss of response.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in